LIMNHealthcare · BiotechnologyLIMN Stock Forecast: Liminatus Pharma, Inc. Price Predictions for 2026-2027
Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 5 of 100 as at 1 Aug 2026 — in the weakest quartile.
LIMN stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Liminatus Pharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (94): Smaller than most of the companies we track.
Issuance (4): The company has been issuing shares or taking on financing, diluting existing holders.
The rank is the raw material. Whether the rules would actually own Liminatus Pharma, Inc. — and when they’d sell — is the membership.
LIMN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on LIMN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
LIMN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Liminatus Pharma, Inc. (LIMN) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- −0.2×
- Price / sales
- —
- Price / book
- −28.0×
- EV / EBITDA
- −0.4×
Cheaper than 78% of US stocks
Cheaper than 98% of US stocks
Cheaper than 64% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- 0.0%
- Net margin
- 0.0%
Higher than 35% of US stocks
Higher than 30% of US stocks
- Return on equity
- 104.0%
- Return on assets
- −1990.4%
- Dividend yield
- —
Higher than 96% of US stocks
Higher than 1% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
LIMN vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LIMN appears on the weeks it earns a place.
Frequently asked questions about LIMN stock
How does Ticker Nerd's model rank LIMN?
As at 1 Aug 2026, Liminatus Pharma, Inc. ranks 5 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (94 of 100).
What is the LIMN stock forecast for 2030?
No analyst covering Liminatus Pharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LIMN are extrapolating price history, which says nothing about the business.
How has LIMN stock performed over the past year?
Liminatus Pharma, Inc. returned -98.1% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Liminatus Pharma, Inc. do?
Liminatus Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies with an emphasis on immuno-oncology approaches.
About Liminatus Pharma, Inc.
Liminatus Pharma Inc. is a clinical-stage biopharmaceutical company focused on developing cancer therapies with an emphasis on immuno-oncology approaches. The company concentrates on immune-modulating treatments designed to target tumors more precisely by harnessing the body’s own immune system. Liminatus Pharma’s lead work includes a Guanylyl Cyclase C (GCC)–targeted vaccine being evaluated in mid-stage clinical trials for colorectal, pancreatic, gastric, and esophageal cancers that express GCC, addressing tumor types with significant unmet medical need. Its programs are positioned within the broader biotechnology and healthcare sectors, contributing to the oncology treatment landscape through novel therapeutic platforms rather than traditional chemotherapies. Liminatus Pharma Inc. operates today as a specialized innovator in cancer drug development, engaging primarily in research, clinical testing, and related translational activities. Founded in 2020 and headquartered in Cerritos, California, the company plays a focused role in the market as an emerging developer of targeted immuno-oncology candidates.
CEO Mr. Chris Kim J.D., L.L.M. · 1 employees · United States · https://liminatuspharma.com